|
| 1,3-dipropyl-8-(3-noradamantyl)xanthine Basic information |
Product Name: | 1,3-dipropyl-8-(3-noradamantyl)xanthine | Synonyms: | 1,3-dipropyl-8-(3-noradamantyl)xanthine;HMR-4902;KW-3902;Rolofylline;8-(Hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,7-dihydro-1,3-dipropyl-1H-purine-2,6-dione;MK-7418;8-(Hexahydro-2,5-methano-pentalen-3a-yl)-1,3-dipropyl-3,7-dihydro-purine-2,6-dione;1H-Purine-2,6-dione, 8-(hexahydro-2,5-methanopentalen-3a(1H)-yl)-3,9-dihydro-1,3-dipropyl- | CAS: | 136199-02-5 | MF: | C20H28N4O2 | MW: | 356.46 | EINECS: | | Product Categories: | | Mol File: | 136199-02-5.mol | |
| 1,3-dipropyl-8-(3-noradamantyl)xanthine Chemical Properties |
Boiling point | 578.0±42.0 °C(Predicted) | density | 1.262±0.06 g/cm3(Predicted) | storage temp. | 2-8°C | solubility | DMSO: soluble20mg/mL | form | solid | pka | 9.23±0.70(Predicted) | color | White to off-white |
| 1,3-dipropyl-8-(3-noradamantyl)xanthine Usage And Synthesis |
Description | KW 3902 is an antagonist of the adenosine A1 receptor (Ki = 0.19 nM). It displays 890-fold selectivity for A1 receptors over A2A receptors and has no activity at A3 receptors. KW 3902 less potently inhibits human organic anion transporter 1 (OAT1; Ki = 7.82 μM). KW 3902 exhibits renal protective effects during hypoxemia in rabbits. | Uses | KW 3902 is an adenosine A1-receptor antagonist, which has recently been shown to alleviate axonopathy caused by human Tau ΔK280. KW 3902 can be considered for the development of a treatment towards hypometabolism and neuronal dysfunction associated with Tau-induced neurodegenerative diseases. | Definition | ChEBI: Rolofylline is an oxopurine. | storage | Store at +4°C |
| 1,3-dipropyl-8-(3-noradamantyl)xanthine Preparation Products And Raw materials |
|